Amgen Expands Crackdown on What It Says Is Misuse of 340B Program

Why It Matters

By tightening oversight, Amgen seeks to protect its revenue and ensure compliance with 340B regulations, while signaling a broader industry shift toward stricter monitoring of discount programs.

Key Takeaways

• Amgen adds claims data verification for all 340B pharmacies.
• New policy targets alleged over‑discounted sales and duplicate billing.
• Pharmacies must submit detailed dispensing records within 30 days.
• Non‑compliant partners risk losing Amgen drug discounts and contracts.
• Industry watchdogs predict broader pharma push for stricter 340B oversight.

Pulse Analysis

The 340B Drug Pricing Program, created in 1992, allows eligible hospitals and clinics to purchase outpatient medicines at steep discounts in exchange for serving vulnerable patients. Over the years, the program has faced criticism for alleged loopholes that let some pharmacies profit from discounts without meeting safety‑net requirements. As federal oversight intensifies, manufacturers are increasingly scrutinizing how their drugs flow through the 340B channel, fearing revenue erosion and reputational risk.

Amgen’s latest directive expands its claims‑data mandate to every pharmacy dispensing its 340B‑eligible products. Under the new rules, pharmacies must upload prescription‑level data—including patient eligibility, dosage, and dispensing dates—within 30 days of sale. Failure to comply can trigger contract termination and loss of discounted pricing. By demanding granular transparency, Amgen aims to detect duplicate billing, over‑discounted sales, and instances where drugs intended for low‑income patients are diverted to higher‑margin markets.

The move underscores a growing trend of pharmaceutical firms taking a proactive stance on 340B compliance, complementing recent actions by the Department of Health and Human Services and state attorneys general. Analysts expect tighter manufacturer oversight to reshape discount‑program economics, potentially prompting pharmacies to reassess participation costs versus benefits. For the broader market, Amgen’s policy may accelerate a shift toward more robust data‑sharing frameworks, fostering greater accountability while preserving the program’s original intent of expanding access to affordable medicines.